A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Furie, Richard; Petri, Michelle; Zamani, Omid; Cervera, Ricard; J. Wallace, Daniel; Tegzová, Dana; Sánchez‐Guerrero, Jorge; Schwarting, Andreas; T. Merrill, Joan; Chatham, Winn; Stohl, William; M. Ginzler, Ellen; R. Hough, Douglas; John Zhong, Z.; W. Freimuth, William; van Vollenhoven, Ronald; Study Group, BLISS-76

doi:10.1002/art.30613

Public

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Published in Arthritis & Rheumatism • Sep 1, 2011

Authors:

Richard Furie

Michelle Petri

Omid Zamani

Abstract

OBJECTIVE: To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab plus standard therapy compared with placebo plus standard therapy in active systemic lupus erythematosus (SLE). METHODS: In a phase III, multicenter, randomized, placebo-controlled trial, 819 antinuclear anti...

Subject

Belimumab

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!